As of March 23, 2026, Lyra Therapeutics's top three insider holders are Maria Palasis (President Ceo, 1.10Mn shares), Harlan Waksal (Executive Chair, 536.97K shares), Jason Cavalier (Chief Financial Officer, 518.55K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Maria Palasis | President Ceo | 1,096,733 | 0 | 08 Jan, 2026 |
| Harlan Waksal | Executive Chair | 536,966 | 0 | 20 Mar, 2024 |
| Jason Cavalier | Chief Financial Officer | 518,547 | 0 | 08 Jan, 2026 |
| Corinne Noyes | See Remarks | 36,667 | 0 | 02 Feb, 2023 |
| Robert E. Richard | Svp, Technical Operations | 30,000 | 0 | 02 Feb, 2023 |
| C Ann Merrifield | 11,328 | 0 | 13 Jun, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Jan, 2026 | Jason Cavalier | Common Stock | D | 769 | $3.36 | 518,547 | D | S |
| 06 Jan, 2026 | Maria Palasis | Common Stock | D | 1,702 | $3.36 | 1,096,733 | D | S |
| 01 Oct, 2025 | Maria Palasis | Employee Stock Option (right to buy) | A | 3,667 | $0.00 | 7,333 | D | A |
| 10 Jul, 2025 | Jason Cavalier | Common Stock | D | 684 | $8.91 | 519,316 | D | S |
| 10 Jul, 2025 | Maria Palasis | Common Stock | D | 1,565 | $8.91 | 1,098,435 | D | S |
| 14 May, 2025 | W Bradford Smith | Restricted Stock Units | A | 32,000 | $0.00 | 32,000 | D | A |
| 14 May, 2025 | C Ann Merrifield | Restricted Stock Units | A | 32,000 | $0.00 | 32,000 | D | A |
| 14 May, 2025 | James R Tobin | Restricted Stock Units | A | 32,000 | $0.00 | 32,000 | D | A |
| 14 May, 2025 | Nancy Lynn Md Snyderman | Restricted Stock Units | A | 32,000 | $0.00 | 32,000 | D | A |
| 08 Jan, 2025 | Maria Palasis | Common Stock | A | 800,000 | $0.00 | 1,100,000 | D | A |
| 09 Dec, 2024 | Harlan Waksal | Performance-based Restricted Stock Units | D | 128,333 | $0.00 | 0 | D | A |
| 09 Dec, 2024 | Maria Palasis | Employee Stock Option (right to buy) | A | 183,333 | $0.00 | 183,333 | D | A |
| 16 Oct, 2024 | Maria Palasis | Common Stock | A | 300,000 | $0.00 | 300,000 | D | A |
| 16 Oct, 2024 | Jason Cavalier | Common Stock | A | 100,000 | $0.00 | 100,000 | D | A |
| 13 Jun, 2024 | W Bradford Smith | Stock Option | A | 30,000 | $0.00 | 30,000 | D | A |
| 13 Jun, 2024 | James R Tobin | Stock Option | A | 30,000 | $0.00 | 30,000 | D | A |
| 13 Jun, 2024 | Nancy Lynn Md Snyderman | Stock Option | A | 30,000 | $0.00 | 30,000 | D | A |
| 13 Jun, 2024 | C Ann Merrifield | Stock Option | A | 30,000 | $0.00 | 30,000 | D | A |
| 13 Jun, 2024 | Konstantin Poukalov | Stock Option | A | 30,000 | $0.00 | 30,000 | D | A |
| 13 Jun, 2024 | Michael Seth Altman | Stock Option | A | 30,000 | $0.00 | 30,000 | D | A |